In today’s recent session, 0.7 million shares of the Mersana Therapeutics Inc (NASDAQ:MRSN) have been traded, and its beta is 1.39. Most recently the company’s share price was $1.38, and it changed around -$0.12 or -8.00% from the last close, which brings the market valuation of the company to $180.08M. MRSN at last check was trading at a discount to its 52-week high of $6.28, offering almost -355.07% off that amount. The share price’s 52-week low was $1.22, which indicates that the recent value has risen by an impressive 11.59% since then. We note from Mersana Therapeutics Inc’s average daily trading volume that its 10-day average is 1.66 million shares, with the 3-month average coming to 1.15 million.
Mersana Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.40. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 2 recommended MRSN as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Mersana Therapeutics Inc is expected to report earnings per share of -0.16 for the current quarter.
Mersana Therapeutics Inc (NASDAQ:MRSN) trade information
Instantly MRSN has been showing red trend so far today with a performance of -8.00% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.6350 on recent trading dayincreased the stock’s daily price by 15.6%. The company’s shares are currently down -40.52% year-to-date, but still down -13.75% over the last five days. On the other hand, Mersana Therapeutics Inc (NASDAQ:MRSN) is -36.99% down in the 30-day period. We can see from the shorts that 8.91 million shares have been sold at a short interest cover period of 7.58 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 54.0% from its current value. Analyst projections state that MRSN is forecast to be at a low of $3 and a high of $3.
Mersana Therapeutics Inc (MRSN) estimates and forecasts
Mersana Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -29.95 percent over the past six months and at a 58.78% annual growth rate that is well above the industry average of 16.70%. The year-over-year growth rate is expected to be -13.81%, down from the previous year.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of 7.64M in revenue for the current quarter. 5 analysts expect Mersana Therapeutics Inc to make 5.9M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 10.7M and 9.24M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -28.60%. Forecasts for the next quarter put sales growth at -36.21%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 11.93%.
MRSN Dividends
Mersana Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.34% of Mersana Therapeutics Inc shares, and 102.08% of them are in the hands of institutional investors. The stock currently has a share float of 103.47%. Mersana Therapeutics Inc stock is held by 152.0 institutions, with ECOR1 CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 15.9479% of the shares, which is about 19.36 million shares worth $38.92 million.
VR ADVISER, LLC, with 9.3292% or 11.33 million shares worth $22.77 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
